Evidence map›Paper›PMID 37926828›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018.

Van Nghiem, Sarah Wood, Rekha Ramachandran, Grant Williams, Darryl Outlaw, Ravikumar Paluri, Young-Il Kim, Olumide Gbolahan

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07146646 (A Phase II Trial of Trifluridine/Tipiracil Plus Oxaliplatin in Patients With Advanced or Metastatic Biliary Tract Cancer Following First-Line Therapy), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07146646 phase2recruitingnot on this map

A Phase II Trial of Trifluridine/Tipiracil Plus Oxaliplatin in Patients With Advanced or Metastatic Biliary Tract Cancer Following First-Line Therapy

TypeinterventionalSponsorCase Comprehensive Cancer CenterRan2025 to 2027Enrolled27ConditionsBiliary Tract Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma, Gallbladder CancerArmsTrifluridine/tipiracil, Oxaliplatin
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Van NghiemUniversity of Alabama at Birmingham School of Public Health, Birmingham, AL, USA.
Sarah WoodDepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Rekha RamachandranDivision of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Grant WilliamsDivision of Hematology/Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Darryl OutlawDivision of Hematology/Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Ravikumar PaluriSection of Hematology/Oncology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Young-Il KimDivision of Preventive Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA.
Olumide GbolahanDepartment of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-8477-4051
University of Alabama at Birmingham · USEmory University · USWake Forest University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInformation about survival outcomes in metastatic biliary tract cancer (BTC) is sparse, and the numbers often quoted are based on reports of clinical trials data that may not be representative of patients treated in the real world. Furthermore, the impact of more widespread adoption of a standardized combination chemotherapy regimen since 2010 on survival is unclear.

methodsWe performed an analysis of the Surveillance, Epidemiology, and End Results database to determine the real-world overall survival trends in a cohort of patients with metastatic BTC diagnosed between the years 2000 and 2017 with follow-up until 2018. We analyzed data for the entire cohort, evaluated short-term and long-term survival rates, and compared survival outcomes in the pre-2010 and post-2010 periods. Survival analysis was performed using the Kaplan-Meier method, and Cox proportional hazard models were used to evaluate factors associated with survival.

resultsAmong 13, 287 patients, the median age was 68 years. There was a preponderance of female (57%) and white (77%) patients. Forty-one percent died within 3 months of diagnosis (short-term survivors) and 20% were long-term survivors (12 months or longer). The median overall survival (OS) for the entire cohort was 4.5 months. Median OS improved post-2010 (4.5 months) compared to pre-2010 (3.5 months) (

conclusionThe real-world prognosis of metastatic BTC is remarkably poorer than described in clinical trials because a large proportion of patients survive less than three months. Over the last decade, the improvement in survival has been minimal.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaAgedBile Ducts, IntrahepaticDatabases, FactualFemaleHumansMiddle AgedMultivariate AnalysisUnited Statesbile duct neoplasmsbiliary tract cancercholangiocarcinomafollow-up studiesprognosisreal-world studiesSurveillance, Epidemiology, and End Results databasesurvival

Identifiers

PMID37926828
PMCPMC10668577
OpenAlexW4388423715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.